May 11, 2022
Invetx Announces Oversubscribed Series B Financing of $60.5 Million to Advance Portfolio of Best-in-Class Veterinary Biotherapeutics
Company positioned to bring portfolio of novel antibody product candidates through development to market approval Round includes new investors F-Prime Capital, Novo Holdings, GV and Eight Roads BOSTON, May 10, 2022–(BUSINESS WIRE)–Invetx, a pioneer in protein-based therapeutics for animal health, announced today that it has raised $60.5 million in an oversubscribed Series B financing. The investment was led by F-Prime …